Health & Biotech Mesoblast and the ASX’s other big biotechs have intrigued investors this year; here’s what’s in store next November 16, 2021 The ASX's big biotechs, particular Mesoblast (ASX:MSB), have had intriguing years in 2021, but there could be more to look… EZZ to use strong FY21 results to expand growth in international markets November 16, 2021 Special Report: A solid performance in FY21 is set to continue for EZZ into this financial year as the company… ASX Pot Stocks: MMJ invests $1 million in Weed Me, Creso plans US ImpACTIVE launch November 15, 2021 MMJ Group Holdings (ASX:MMJ) MMJ Group was up 9.37% today, after making a follow on CA$1 million investment in Canada’s… ASX Health Stocks: Mesoblast jumps 10pc on Phase 3 trial results for chronic heart failure November 15, 2021 The ASX 200 Health Index (XHJ) is up by 1.5% at the time of writing, compared to the broader index… PharmAust expands studies in NZ, one step closer towards a Phase 3 trial for canine cancer November 15, 2021 Special Report: The expansion of PharmAust’s Phase 2b studies in New Zealand is the first step towards launching a Phase… Dr Boreham’s Crucible: Breaking down ASX aspirant Artrya’s AI heart disease warning system November 15, 2021 Heart disease remains the world’s number one killer, yet the scourge remains under-appreciated relative to other major ailments such as… ScoPo’s Powerplays: AGM season ‘flushes out negative surprises’ but creates buying opportunities November 12, 2021 Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains… ASX Health Stocks: Cannabis play AusCann commences study of CBD on spinal cord injury November 12, 2021 The ASX 200 Health Index (XHJ) is down by 2.2% at the time of writing, compared to the broader index… ASX Health Stocks: UBI partners with Mayo Clinic, while Medlab jumps 8pc after divestment November 11, 2021 The ASX 200 Health Index (XHJ) is down by 1.0% at the time of writing, compared to the broader index… Check Up: Imagion and Invion both target breast cancer clinical trials November 11, 2021 It’s been a mixed two weeks for small-cap health companies, with only 40 companies gaining ground, 72 losing it and… Next» « Previous